Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689219 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Nabil Adra.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02689219: Clinical Trial Phase 2 study, sponsored by Nabil Adra.
NCT02689219 is a Phase 2 study that was terminated before completion, run by Nabil Adra. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02689219, a Phase 2 study, was terminated before completion, sponsored by Nabil Adra.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
Primary Outcome
Measured by RECIST v1.1 and tumor markers (AFP and BhCG). CR - disappearance of all target lesions and normalization of serum tumor markers for at least 4 weeks. When only evidence of disease is elevated serum tumor markers, then values must fall below the upper limit of normal for the assay and remain at that level for at least 4 weeks. PR - at least a 30% decrease in the sum of the diameters of target lesions compared to the baseline sum diameters for at least 2 measurements 1 month apart with
Interventions
- DRUG Brentuximab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 2 |
Why NCT02689219 stopped before completion
NCT02689219 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Brentuximab Vedotin is the first listed.
NCT02689219 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02689219 about?
NCT02689219 is a clinical study titled "Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors". This is a Phase II study to evaluate the activity of brentuximab vedotin in relapsed/refractory non-seminomatous germ cell tumors (NSGCT).
What is the current status of trial NCT02689219?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-03-09. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT02689219?
The interventions under investigation include: Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT02689219?
This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02689219's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI